secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001104659-24-060529
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara Therapeutics Q1 2024 net loss $0.56/shr, revenue $2.1M; NP data by end 2Q24
--------------------------------------------------------------------------------

- Net loss $30.7M ($0.56/shr) vs $26.7M ($0.49) in Q1 2023; total revenue $2.1M down from $6.2M.
- Cash & marketable securities $69.8M at March 31, 2024, down from $100.8M at Dec 31, 2023; ops used $30.5M.
- KOURAGE 1 Part A topline NP results expected by end of Q2 2024; 214 patients enrolled, not powered for significance.
- KORSUVA injection net sales $1.8M in Q1 2024; TDAPA expired March 31, now reimbursed via ESRD bundle.
- Restructuring expenses $2.4M related to workforce reduction; R&D $22.0M vs $24.3M a year ago.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465924060529/0001104659-24-060529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465924060529/tm2414193d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-060529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer